The FDA grants a humanitarian device exemption for CVRx's Barostim neo legacy device for treating drug-resistant hypertension.
CVRx said yesterday that it won a humanitarian device exemption from the FDA for its Barostim neo legacy device, to treat drug-resistant hypertension.
An analysis of Medtronic's failed Symplicity-3 renal denervation trial highlights several 'confounding' factors that may have contributed to a missed efficacy endpoint, suggesting a way forward for more RDN studies.
Vascular Dynamics reports raising $10 million out of a hoped-for $23 million funding round for its MobiusHD anti-hypertension implant.
Vascular Dynamics said it raised nearly $10 million from a group of unnamed investors for the hypertension implant it's developing.
The Mountain View, Calif.-based startup reported raising $9.7 million in an offering of stock, warrants and other securities as part of a proposed $22.9 million funding round.
Sympara Medical quietly secures $5.5 million in funding from a handful of investors as it develops a device to treat hypertension.
Stealthy Sympara Medical quietly secured $5.5 million in funding from a handful of investors for the hypertension device it's developing.
San Francisco-based Sympara disclosed the funding in a regulatory filing, after recording $4.3 million with the SEC in 2013.
Ablative Solutions begins testing its infusion ablation catheter as a potential treatment for hypertension.
Another trial of Medtronic's Symplicity renal denervation device in treating hypertension shows no benefit compared with a sham procedure.
A roundup of studies released at the annual Transcatheter Cardiovascular Therapies conference in Washington this week.
Here's a look at some of the news coming out of Washington at the 26th annual Transcatheter Cardiovascular Therapies conference this week: